Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Jan 16, 2012
0
0